Clinical Research Profession Takes Major Step Forward
Movement to Unify Physician Investigators into One Comprehensive Organization Progresses as ACRP and AAPP Form Official Affiliation
Alexandria, VA – The Boards of Directors of the Association of Clinical Research Professionals (ACRP) and the American Academy of Pharmaceutical Physicians (AAPP) announced today that both organizations have signed a Definitive Agreemment signifying a formal affiliation between the two groups and their related Education Foundation activities. In this affiliation, AAPP creates a professional medical society known as the Academy of Pharmaceutical Physicians and Investigators (APPI) which becomes an affiliate of ACRP.
This action creates a single, global organization that will unify, certify and educate all members of the Clinical Research Team™ – an important development for the clinical research profession.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
